GM22128
LCL from B-Lymphocyte
Description:
BARTH SYNDROME; BTHS
TAFAZZIN; TAZ
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases |
Biopsy Source
|
Peripheral vein
|
Cell Type
|
B-Lymphocyte
|
Tissue Type
|
Blood
|
Transformant
|
Epstein-Barr Virus
|
Sample Source
|
LCL from B-Lymphocyte
|
Race
|
Hispanic/Latino
|
Ethnicity
|
MEXICAN
|
Family History
|
N
|
Relation to Proband
|
proband
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin confirmed by LINE assay |
|
Gene |
TAZ |
Chromosomal Location |
Xq28 |
Allelic Variant 1 |
L212P; BARTH SYNDROME |
Identified Mutation |
LEU212PRO |
Remarks |
Clinically affected; two affected deceased uncles and two affected cousins (one deceased at 10 days of age); cholesterol at >1 year of age was 97 mg/dl; 3-methylglutaconate in plasma is 3218 nmol/l; onset of dilated cardiomyopathy at age 4 months; donor subject is hemizygous for a T>C change in exon 8 of the TAZ (G4.5) gene (c.635T>C) resulting in the substitution of proline for leucine at codon 212 [Leu212Pro (L212P)] |
Johnston J, Kelley RI, Feigenbaum A, Cox GF, Iyer GS, Funanage VL, Proujansky R, Mutation characterization and genotype-phenotype correlation in Barth syndrome American journal of human genetics61:1053-8 1997 |
PubMed ID: 9345098 |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not Inactivated |
Substrate |
None specified |
Subcultivation Method |
dilution - add fresh medium |
Supplement |
- |
|
|